1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA) / NIH. This program aims to enhance the training of a workforce skilled in biomedical, behavioral, and clinical research, particularly regarding substance use disorders. It supports educational activities that prepare clinicians and clinical researchers.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) | Research Funding National Institutes of Health NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.
The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development This notice of funding opportunity (NOFO) is intended to support research education activities for clinicians, clinicians in training, and clinical researchers that enhance the knowledge of substance use and substance use disorder (SUD) research and provide opportunities for active participation in related research.
This mechanism may not be used to support non-research-related clinical training. The proposed research education programs must include both courses for skills development and research experiences with primary emphasis on research experiences. Letter of Intent Deadlines: 30 days before the application due date.
R25 Application Deadlines: March 11, 2025; Aug 12, 2025; Nov 12, 2025; March 11, 2026; Aug 12, 2026; PAR-25-204 Expiration Date New Date August 13, 2026 per issuance of NOT-DA-26-015 . (Original Expiration Date: November 13, 2027 ) The sponsoring institution must assure support for the proposed program.
Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program. Institutions with existing Ruth L.
Kirschstein National Research Service Award (NRSA) institutional training grants (e.g., T32) or other Federally funded training programs may apply for a research education grant provided that the proposed educational experiences are distinct from those training programs receiving federal support.
In many cases, it is anticipated that the proposed research education program will complement ongoing research training occurring at the applicant institution. The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program.
The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. Although the size of the award may vary with the scope of the research education program proposed, application budgets are limited to $350,000 in direct costs annually and must reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.
The total project period, however, may not exceed 5 years. Medical - Clinical Science
According to the current listing, eligibility includes: Research institutions and other eligible organizations in the U.S. that can provide educational activities for clinicians and clinical researchers. Confirm the full requirements in the official notice before applying.
NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) is funded by National Institute on Drug Abuse (NIDA) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) / NIH. This funding opportunity invites applications for innovative research aimed at developing and implementing interventions to prevent and treat substance use disorders (SUDs) and overdose. It encourages studies that can rapidly advance candidate solutions towards regulatory approval or clinical use, while also addressing co-morbid SUDs.
Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) / NIH. This Small Business Innovation Research (SBIR) funding opportunity supports small business concerns (SBC) to develop technologies for commercialization that address health-related social needs impacting Substance Use Disorders (SUD), excluding alcohol use disorder.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article